199 related articles for article (PubMed ID: 36074460)
21. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
[TBL] [Abstract][Full Text] [Related]
24. Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer.
Sokolenko AP; Sultanova LV; Stepanov IA; Romanko AA; Venina AR; Sokolova TN; Musayeva HS; Tovgereeva MY; Magomedova MK; Akhmatkhanov KU; Vagapova EI; Suleymanov EA; Vasilyeva EV; Bakaeva EK; Bizin IV; Aleksakhina SN; Imyanitov EN
Cancer Med; 2023 Feb; 12(3):3167-3171. PubMed ID: 36000185
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
26. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
27. Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
Samusieva A; Serga S; Klymenko S; Rybchenko L; Klimuk B; Zakhartseva L; Gorovenko N; Lobanova O; Rossokha Z; Fishchuk L; Levkovich N; Medvedieva N; Popova O; Cheshuk V; Inomistova M; Khranovska N; Skachkova O; Michailovich Y; Ponomarova O; Kozeretska I
Breast Cancer Res Treat; 2022 Oct; 195(3):453-459. PubMed ID: 35930098
[TBL] [Abstract][Full Text] [Related]
28. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer.
Wong EM; Southey MC; Fox SB; Brown MA; Dowty JG; Jenkins MA; Giles GG; Hopper JL; Dobrovic A
Cancer Prev Res (Phila); 2011 Jan; 4(1):23-33. PubMed ID: 20978112
[TBL] [Abstract][Full Text] [Related]
29. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
30. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
[TBL] [Abstract][Full Text] [Related]
31. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
[TBL] [Abstract][Full Text] [Related]
32. The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.
Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
34. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Mahfoudh W; Bettaieb I; Ghedira R; Snoussi K; Bouzid N; Klayech Z; Gabbouj S; Remadi Y; Hassen E; Bouaouina N; Zakhama A
J Transl Med; 2019 Apr; 17(1):123. PubMed ID: 30975216
[TBL] [Abstract][Full Text] [Related]
35. Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Morizono A; Tanabe M; Ikemura M; Sasaki T; Ushiku T; Seto Y
J Hum Genet; 2021 Aug; 66(8):785-793. PubMed ID: 33640902
[TBL] [Abstract][Full Text] [Related]
36. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
37. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Wong-Brown MW; Meldrum CJ; Carpenter JE; Clarke CL; Narod SA; Jakubowska A; Rudnicka H; Lubinski J; Scott RJ
Breast Cancer Res Treat; 2015 Feb; 150(1):71-80. PubMed ID: 25682074
[TBL] [Abstract][Full Text] [Related]
39. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
[TBL] [Abstract][Full Text] [Related]
40. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
